Your session is about to expire
← Back to Search
NA
Cardiovascular Exercise for Type 2 Diabetes (REACH Trial)
N/A
Recruiting
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, approximately 4 months
Awards & highlights
REACH Trial Summary
This trial will study whether exercise can help improve cardiac function and exercise performance in people with type 2 diabetes.
Who is the study for?
This trial is for sedentary adults with a BMI of 25-40, who may or may not have type 2 diabetes. It's not suitable for those with uncontrolled high blood pressure, taking certain heart and diabetes medications, smokers, or people with cardiovascular disease, lung conditions like asthma, severe nerve damage in limbs (peripheral neuropathy), anemia, liver or kidney disease.Check my eligibility
What is being tested?
The study investigates if cardiovascular exercise can improve heart and muscle function by overcoming insulin resistance in muscles—a condition common in type 2 diabetes. Participants will undergo exercise training to see if it helps their bodies use insulin better and increases blood flow to the heart and muscles.See study design
What are the potential side effects?
While the trial involves physical exercise which is generally safe and beneficial, potential side effects might include typical workout-related issues such as muscle soreness or strain. People with existing health conditions should consider risks associated with new exercise routines.
REACH Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, approximately 4 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, approximately 4 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in insulin sensitivity
Change in peak oxygen consumption (VO2)
REACH Trial Design
2Treatment groups
Experimental Treatment
Group I: Type 2 DiabetesExperimental Treatment1 Intervention
Participants aged 30-55 with type 2 diabetes
Group II: Healthy overweight controlExperimental Treatment1 Intervention
Participants aged 30-55 with BMI 25-40 without type 2 diabetes
Find a Location
Who is running the clinical trial?
University of Colorado, DenverLead Sponsor
1,737 Previous Clinical Trials
2,149,156 Total Patients Enrolled
University of VirginiaOTHER
754 Previous Clinical Trials
1,244,923 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,359 Previous Clinical Trials
4,315,353 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am currently taking medication such as beta blockers, calcium channel blockers, insulin, or TZDs.You have smoked in the past year.You do not engage in physical activity for at least 1 hour per week.I have a physical condition that limits my ability to exercise.Your blood sugar levels are higher than normal for someone without diabetes, or excessively high if you have type 2 diabetes.Your weight in relation to your height falls within a certain range.Your blood pressure is not well controlled, with high numbers for both systolic (top number) and diastolic (bottom number) measurements.I have anemia.I may or may not have type 2 diabetes.I am not pregnant, nursing, or on hormonal therapy except for contraceptives.I am a woman who has gone through menopause.I have nerve damage in my hands or feet.I have liver or kidney disease.You have type 1 diabetes.You currently smoke or use tobacco products.I have a diagnosed heart condition.I have asthma or another lung condition that blocks airflow.
Research Study Groups:
This trial has the following groups:- Group 1: Type 2 Diabetes
- Group 2: Healthy overweight control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who is eligible to join this medical experiment?
"This trial calls for 150 volunteers with type 2 diabetes between the ages of 30 and 55. Applicants must be sedentary (no more than 1 hour a week of physical activity), have a BMI ranging from 25 to 40, and can be either men or women, both with and without type 2 diabetes."
Answered by AI
What is the total capacity of participants in this clinical experiment?
"Affirmative. As indicated on clinicaltrials.gov, this study is currently seeking potential participants and was last updated on August 2nd 2022. This project began recruitment efforts on June 17th of the same year and hopes to enroll 150 individuals between two sites."
Answered by AI
Is enrollment open for this research trial?
"Affirmative. Clinicaltrials.gov provides evidence that this research is actively recruiting volunteers, having first been posted on June 17th 2022 and most recently updated on August 2nd 2022. This medical experiment requires 150 individuals from 2 clinical trial sites to participate."
Answered by AI
Is eligibility for this study limited to adults?
"As indicated by the requirements for participation, potential participants must be between 30 and 55 years old."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger